Turnstone Biologics (NASDAQ:TSBX – Get Free Report) and AbCellera Biologics (NASDAQ:ABCL – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, risk, analyst recommendations, valuation and institutional ownership.
Institutional & Insider Ownership
52.5% of Turnstone Biologics shares are held by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are held by institutional investors. 32.1% of Turnstone Biologics shares are held by company insiders. Comparatively, 28.9% of AbCellera Biologics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Analyst Recommendations
This is a breakdown of current ratings and price targets for Turnstone Biologics and AbCellera Biologics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Turnstone Biologics | 1 | 1 | 0 | 0 | 1.50 |
| AbCellera Biologics | 0 | 1 | 4 | 1 | 3.00 |
Profitability
This table compares Turnstone Biologics and AbCellera Biologics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Turnstone Biologics | N/A | -171.86% | -128.13% |
| AbCellera Biologics | -511.88% | -16.17% | -12.24% |
Earnings and Valuation
This table compares Turnstone Biologics and AbCellera Biologics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Turnstone Biologics | $19.31 million | 0.43 | -$70.84 million | ($2.05) | -0.17 |
| AbCellera Biologics | $28.83 million | 45.09 | -$162.86 million | ($0.55) | -7.91 |
Turnstone Biologics has higher earnings, but lower revenue than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Turnstone Biologics, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Turnstone Biologics has a beta of 1.36, indicating that its share price is 36% more volatile than the S&P 500. Comparatively, AbCellera Biologics has a beta of 0.65, indicating that its share price is 35% less volatile than the S&P 500.
Summary
AbCellera Biologics beats Turnstone Biologics on 10 of the 15 factors compared between the two stocks.
About Turnstone Biologics
Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.
About AbCellera Biologics
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company’s preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
Receive News & Ratings for Turnstone Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Turnstone Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
